BerandaDBV • FRA
add
DBV Technologies SA
Tutup sebelumnya
€2,08
Rentang hari
€1,89 - €1,91
Rentang tahun
€0,44 - €2,00
Kapitalisasi pasar
247,87 jt EUR
Volume Rata-Rata
291,00
Rasio P/E
-
Hasil dividen
-
Bursa utama
EPA
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 753,00 rb | -46,48% |
Biaya operasional | 27,37 jt | -8,66% |
Laba bersih | -27,08 jt | 0,97% |
Margin laba bersih | -3,60 rb | -85,03% |
Penghasilan per saham | -0,23 | 91,18% |
EBITDA | -25,67 jt | 9,96% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 12,96 jt | -87,23% |
Total aset | 50,56 jt | -65,34% |
Total liabilitas | 47,69 jt | 39,27% |
Total ekuitas | 2,87 jt | — |
Saham yang beredar | 136,72 jt | — |
Harga terhadap nilai buku | 69,33 | — |
Tingkat pengembalian aset | -114,52% | — |
Tingkat pengembalian modal | -299,45% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -27,08 jt | 0,97% |
Kas dari operasi | -19,67 jt | 43,31% |
Kas dari investasi | -375,00 rb | 82,41% |
Kas dari pembiayaan | 45,00 rb | 172,58% |
Perubahan kas bersih | -19,49 jt | 51,07% |
Arus kas bebas | -9,34 jt | 66,16% |
Tentang
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration. Wikipedia
Didirikan
29 Mar 2002
Situs
Karyawan
106
